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A B S T R A C T
BK virus associated nephropathy (BKVAN) in transplanted kidney, although recognized as a distinct entity in the
1970-es, continues to represent a challenge in kidney transplantation, mainly because the optimal treatment approach
has not been determined yet. The fact that about 10–20% of patients have simultaneously some stage of acute rejection,
complicate the treatment even more. Herein we present a case of BK nephropathy in the patient, one year after combined
liver and kidney transplantation, complicated by episode of acute T-cell mediated rejection. Identification of decoy cells
by cytology urine exam in patient with acute kidney graft function deterioration, raised suspicion of BKVAN. Diagnosis
has been made by histological examination and confirmed with immunohistochemical staining for BK virus in kidney
graft biopsy. One month after he had been treated for BKVAN with intravenous immunoglobulin, leflunomide and over-
all immunosuppression therapy reduction, there was further deterioration of graft function due to an episode of acute
T-cell mediated rejection (Banff classification IA). He received 500 mg of metilprednisolon intravenously and myco-
phenolate mofetil had been reintroduced, which resulted in slow partial recovery of the graft function, but never to the
baseline values. For the past two years his renal graft function has been stable, maintaining lower levels of immuno-
supressive therapy. According to our knowledge this is the first documented case of BK virus associated nephropathy, di-
agnosed and confirmed with immunohistochemical staining of tissue from kidney biopsy in Croatia.
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Introduction
BK polyomavirus, first isolated in urine of patients
with transplanted kidney and ureteric stenosis in 1971.,
has been correlated later with distinct kidney disease in
transplanted kidney. In the late 1990-ties many cases of
polyoma virus or BK virus associated nephropathy
(PVAN or BKVAN) were reported worldwide1–6. Inci-
dence of BKVAN in renal transplant recipients varies
from 1–10%, regarding different immunosuppressive
protocols7, resulted in 50% graft loss in the early series
of patients3,4,6,8. Transplant kidney biopsy is the gold
standard for diagnosing BKVAN9. Demonstration of
polyomavirus cyopathic changes in renal tubular epi-
thelium on light microscopy, should be confirmed by
immunohistochemical staining for BK virus5,6,10. There
are 3 main histological patterns: A with cytopathic/
cytolitic changes with absent or minimal inflamma-
tion, B with cytopathic/cytolitic changes with patchy or
diffuse tubulointerstitial inflammation and atrophy,
and C represents graft sclerosis11. Focal distribution of
the disease in the kidney could result in false negative
biopsy, especially in the early phase of disease. Addi-
tional problem appears in the case of simultaneous
acute T-cell mediated rejection, because inflammatory
infiltrates and tubulitis could be also a part of immune
response to the BK virus infection12. Presence of other
signs of rejection like endarteritis, positive C4d, or
fibrinoid arterial necrosis could help defining between
two entities.
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Different screening options and early therapeutic in-
terventions resulted lately in lower incidence of graft loss
in patients with BKVAN. Screening the urine for cells
with viral inclusions, so called decoy cells, is a primary
screening option in many transplant centers. BKV in-
fected decoy cells mostly originate from the epithelium of
the bladder and urethers, but part of them come directly
from the renal tubules and precede appearance of BKVAN
for about five to six months13.
Different accuracy of that method has been observed
in different transplant centers, with positive predictive
value from 40 to 90%, probably due to differences in urin
examination method, as well as to the extent of histologic
kidney sample evaluation11,14,15. Authors fromUniversity
of Maryland School of Medicine have found the highest
positive predictive value of urine cytology in evaluation
of 413 patients, whom they performed detailed pato-
hystologic analysis of biopsied kidney tissue with multi-
ple immunohistochemical staining for BK in different
parts of sample, which resulted in relatively high propor-
tion of positive biopsies11.
Quantitative and qualitative determination of BK vi-
rus in blood and urine by polymerase chain reaction
(PCR), became recently the screening method of choice
in many transplant centers7,9. BK viruria is typically fol-
lowed within weeks by the development of BK viremia
and certain threshold values (>104 viral copies/mL) have
been suggested to predict BKVAN, but there are consid-
erable overlap of these values between recipients in dif-
ferent stages of the disease13,16,17. It is widely accepted,
that reduction of overall immunosuppression therapy
should be the first intervention for patients with BKVAN7,
with different approaches in certain transplant cen-
ters18–20. Several adjuvant therapeutic agents (cidofovir,
leflunomide and intravenous immunoglobulins) have
been used empirically as single agent, or combined to
each other, always with immunosuppressive therapy re-
duction, and those data were mostly retrospectively ana-
lyzed21. Reduction of immunosuppressive therapy is com-
plicated in 25% of patients with some episode of acute,
mostly T-cell mediated rejection, often responsive to ste-
roid treatment5,7,20.
Case Report
Herein we present a case of 20 years old Caucasian,
whom were simultaneously transplanted liver and kid-
ney in June 2006. His original disease was ARPKD and
idiopathic liver fibrosis. At the time of transplantation
CDC cross match was positive, which we accept for pa-
tients with liver and combined liver-kidney transplanta-
tion in our centre. Induction therapy with IL-2 receptor
monoclonal antibody daclizumab and steroids was used,
followed by maintenance therapy with tacrolimus, myco-
phenolate mofetil (MMF) and steroids. Early function of
both grafts were excellent. There were some transient el-
evation of hepatic enzymes, but without any signs of
acute rejection on liver biopsy.
One year post transplant there was an acute deterio-
ration of renal graft function, considered prerenal, fol-
lowing an episode of acute viral gastroenteritis, but with-
out improvement to fluid replacement. Simultaneously
urine citology revealed decoy cells and kidney biopsy was
performed. Histology showed characteristic basophilic
nuclear viral inclusions in epithelial cells of renal tu-
bules, with diffuse inflammatory infiltrates and tubu-
litis, but also with areas of tubular atrophy, which was
consistent with florid (histology pattern B313) BKVAN
(Figure 1). Diagnosis was confirmed by immunohisto-
chemical staining for BK virus (Figure 2). The patient
has been treated with 25 grams of intravenous immuno-
globulin for 4 days and mycophenolate mofetil was re-
placed by 100 mg leflunomide with reduction of tacro-
limus dose. After short period (1.5 month) of stable renal
function, kidney biopsy has been repeated for further de-
terioration of graft function. Histology revealed acute
T-cell mediated rejection (IIA, according to Banff classi-
fication22), with negative staining for BK virus, and we
treated the patient with 500 mg of metilprednisolon and
mycophenolate mofetil has been reintroduced, but kept
at the lower dose. These resulted in slow partial recovery
of the graft function, but never to the baseline values.
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Fig. 1. BK viral inclusions in the renal tubular cells.
Fig. 2. Positive immunohistochemical staining for BK virus in
renal tubular cells.
For the past two years we have been maintaining his
immunosuppressive regiment at the lower levels, suc-
ceeding to maintain his renal graft function stable (Fig-
ures 3 and 4).
Discussion
Two different screening and intervention protocols
have been proposed by two large transplant centers. One
is based on urine citology screening, with evaluation of
renal biopsy when there is persistence of decoy cells in
urine or viremia independently of the renal function11,18.
This could potentially establish BK nephropathy in early
phase of the disease, but higher rate of false negative bi-
opsies may be encountered in that early stage, because of
focal parenchimal involvement.
The other approach, proposed by Brennan and co-
workers, is quantitative measurement of BK viremia,
with certain cut off titer, when they reduce immuno-
suppression in step manure, without performing kidney
biopsies. Although there is concern that this could lead to
much higher percentage of acute cellular rejection, just
one patient in that group developed acute rejection epi-
sode20. There is also a concern about cost benefit for each
screening procedure, especially for transplant centers
with low incidence of the disease23.
In our center urine citology screening has been intro-
duced in 2007, as well as protocol biopsies of trans-
planted kidney. Total of 206 kidneys, single or combined
with pancreas or liver, have been transplanted in Clinical
hospital Merkur in the period from 2003 to September
2009, and 3 patients have been diagnosed with BKVAN
(1.3%). Lately PCR test for BK viremia is also available.
The most appropriate screening protocol is yet to be de-
termined.
Our patient has been diagnosed in the phase of overt
disease, and we treated him primarily with immunosup-
pression reduction and empirically with adjuvant agents,
according to several studies published at that time24,25. It
could be suspected that rapid discontinuation of MMF
led to acute cellular rejection, because Brennan and co-
workers found very low rate of acute rejection in patients
treated for BKVAN with slow stepwise decrease in im-
munosuppression therapy, especially MMF dose18,20. Dif-
ferent approaches have been used regarding reduction of
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Fig. 3. Estimated glomerular filtration rate calculated by Cockroft Gault formula in mililiters per minute.
Fig. 4. Tacrolimus concentration in nanograms per mililiter in plasma.
maintenance immunosuppression therapy, majority start-
ing with MMF dose reduction, or complete elimination,
followed by calcineurin inhibitor dose reduction18, but re-
cently tested association between BKN and individual
immunosuppressive agents showed also significant asso-
ciation of BKVAN with tacrolimus and prednisone, rather
than MMF, suggesting that reduction of tacrolimus dose
could be the first step in reduction of maintenance im-
munosuppression19. Signs of endoarteritis in second
biopsy and negative immunohistochemistry for BK, al-
though it could be false negative, based our decision to
treat the patient with corticosteroid bolus, and reintro-
duced MMF, but kept the dose of both MMF and ta-
crolimus at low levels. Retaining the immunosuppressive
therapy at low levels for two years after that, resulted in
stable GFR for more than 2 years, which is in accordance
with other studies.
Conclusion
According to our knowledge this is the first documen-
ted case of BK virus associated nephropathy, diagnosed
and confirmed with immunohistochemical staining of
bioptic kidney tissue in Croatia. Prospective, multicen-
tric studies are needed to assess different screening and
treatment approaches. Early diagnosis with close moni-
toring of renal function seems to represent the most effi-
cacious tool in prevention of graft loss, but longer fol-
low-up is necessary to determine the impact of immuno-
suppression reduction on the long term graft outcomes.
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PRVI POTVR\ENI SLU^AJ BK VIRUSNE NEFROPATIJE U BOLESNIKA SA TRANSPLANTIRANIM
BUBREGOM U HRVATSKOJ: KORI[TENJE CITOLO[KE ANALIZE URINA U OTKRIVANJU
BOLESTI
S A @ E T A K
BK virusna nefropatija, koja je prepoznata kao posebni entitet u transplantiranom bubregu jo{ tijekom 1970-tih
godina, i dalje predstavlja dijagnosti~ki i terapijski izazov u transplantacijskoj medicine. Otprilike 10–20% bolesnika
istovremeno razvije odre|eni stupanj akutnog odbacivanja grafta bubrega, {to dodatno komplicira pristup lije~enju.
Prikazujemo slu~aj nefropatije uzrokovane BK virusom u bolesnika, godinu dana nakon istovremene transplantacije
bubrega i jetre, ~ije lije~enje je dodatno komplicirala epizoda akutnog odbacivanja bubrega. Temeljem citolo{ke analize i
nalaza tzv. »decoy« stanica u urinu bolesnika sa akutnim pogor{anjem funkcije grafta bubrega, postavljena je sumnja
na BK virusnu nefropatiju, a dijagnoza je postavljena temeljem patohistolo{ke analize bioptata tkiva bubrega i speci-
fi~nog imunohistokemijskog bojenja tkiva na BK virus. Bolesnika smo lije~ili smanjenjem ukupne doze imunosupre-
sivne terapije, uz adjuvantnu intravensku primjenu humanog imunoglobulina, te zamjenom mikofenolat mofetila sa
leflunomidom. Mjesec dana nakon po~etka lije~enja dolazi do daljnjeg pogor{anja bubre`ne funkcije, uzrokovane pato-
histolo{ki dokazanom epizodom akutnog odbacivanja posredovanog T-limfocitima. Bolesnik je lije~en parenteralno Solu-
medrolom, uz ponovo uvo|enje mikofenolat mofetila, ~ime se funkcija grafta bubrega djelomi~no oporavlja i ostaje
stabilna tijekom posljednje dvije godine, uz trajno ni`u razinu ukupne imunosupresivne terapije. Temeljem na{eg sa-
znanja, radi se o prvom potvr|enom slu~aju BK nefropatije u bolesnika s transplantiranim bubregom u Hrvatskoj, ~ija
je dijagnoza postavljena temeljem specifi~nog imunohistokemijskog bojenja tkiva bubrega na BK virus.
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